ContextVision AB (0L8Z), a Sweden-based medical imaging software specialist listed on the Oslo Stock Exchange under ticker CONTX, has published its interim report for the third quarter of 2026, revealing revenue of 26.5 MSEK compared with 23.7 MSEK in the prior-year period, an increase of 11.5%. Underlying revenue growth, adjusted for timing of revenue recognition and translational foreign exchange effects, reached approximately 34.5% for the quarter. The company also initiated a share buyback programme during the period and reported a sharply improved EBITDA margin of 27.0%, up from 5.7% a year earlier, signalling a material step-change in profitability that investors will be watching closely.

Key Points

  • ContextVision AB (0L8Z), listed on the Oslo Stock Exchange as CONTX
  • Q3 2026 revenue rose 11.5% to 26.5 MSEK, with adjusted underlying growth of approximately 34.5%
  • EBITDA margin expanded to 27.0% (Q3 2025: 5.7%); adjusted EBITDA margin reached 34.7%
  • Investors should watch progress on the BeamWorks partnership, the University of Washington liver disease clinical programme, and Q4 contract conversions

ContextVision Q3 2026 Financial Results: Revenue, EBITDA and Cash Flow Improvement

ContextVision recorded Q3 2026 revenue of 26.5 MSEK against 23.7 MSEK in Q3 2025. A refined assessment of revenue recognition timing reduced reported revenue by 4.1 MSEK in the quarter, while a translational foreign exchange effect added a marginal 0.1 MSEK. EBITDA rose to 7.1 MSEK from 1.4 MSEK, and adjusted EBITDA — which excludes 2.0 MSEK of Data Quality investments — reached 9.2 MSEK, a margin of 34.7%. Cash flow from operating activities turned firmly positive at 7.2 MSEK, compared with negative 2.0 MSEK in the prior-year quarter. Earnings per share were 0.06 SEK versus 0.00 SEK previously, with adjusted earnings per share of 0.09 SEK against 0.03 SEK.

Nine-Month 2026 Performance Reflects Broad-Based Growth Across ContextVision's Software Business

For the nine months ended in Q3 2026, ContextVision reported cumulative revenue of 90.3 MSEK, up 14.9% from 78.6 MSEK in the equivalent prior-year period. Nine-month EBITDA reached 22.4 MSEK, delivering a margin of 24.8%, compared with 2.0 MSEK and a 2.5% margin a year earlier. Adjusted EBITDA for the nine months was 30.7 MSEK at a 34.0% margin, after adjusting for 8.3 MSEK of Data Quality investments. Operating cash flow for the nine months was 22.1 MSEK versus negative 0.2 MSEK previously, and adjusted earnings per share improved to 0.30 SEK from 0.08 SEK.

Chinese Market Licence Sales and BeamWorks Partnership Drive ContextVision's Strategic Progress

Licence revenue was identified in the announcement as the primary growth driver in Q3 2026, with notably positive momentum among customers in China. ContextVision, which supplies image enhancement software to manufacturers of ultrasound, X-ray and MRI equipment globally, also advanced discussions with BeamWorks Inc., a South Korean medical AI company, aiming to jointly develop and launch products using AI and computer vision for real-time detection of anatomical structures and abnormalities. The company stated it will provide a further update when more progress has been made, meaning the collaboration's commercial terms have not yet been finalised.

Liver Biomarker Clinical Programme and Industry Shift Toward Application-Specific Imaging

ContextVision's clinical programme for liver disease diagnostics at the University of Washington had enrolled approximately 25 patients as of the report date, with recruitment described as demanding due to specific clinical eligibility criteria. The company highlighted that a leading global ultrasound manufacturer had discontinued general imaging systems to focus on procedural imaging, particularly interventional cardiology — a development the company views as external validation of its own strategic focus on quantitative imaging and liver biomarkers. A share buyback programme, authorised at the AGM in May 2026, was also initiated during the quarter.